1. Home
  2. MTA vs CADL Comparison

MTA vs CADL Comparison

Compare MTA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

HOLD

Current Price

$9.08

Market Cap

636.3M

Sector

N/A

ML Signal

HOLD

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$10.62

Market Cap

694.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTA
CADL
Founded
1983
1999
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
636.3M
694.6M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
MTA
CADL
Price
$9.08
$10.62
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$9.00
$19.00
AVG Volume (30 Days)
405.9K
1.1M
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
N/A
$125,000.00
Revenue This Year
$81.63
N/A
Revenue Next Year
$62.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.09
$4.35
52 Week High
$9.30
$11.36

Technical Indicators

Market Signals
Indicator
MTA
CADL
Relative Strength Index (RSI) 70.69 60.83
Support Level $6.33 $9.18
Resistance Level $9.25 $11.36
Average True Range (ATR) 0.33 0.47
MACD 0.17 0.04
Stochastic Oscillator 89.24 84.47

Price Performance

Historical Comparison
MTA
CADL

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA, with the majority generated from Brazil.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: